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Abstract 
BACKGROUND: Prostatic cancer is one of the most common cancers of males in a Sudanese population. The 
early detection is very important, as it is only curable at an early stage.  
AIM: The objective of this study was to investigate the expression pattern of Ki-67 in benign and malignant 
prostatic lesions to improve the diagnosis that may help in better management and prevention of disease. 
MATERIAL AND METHODS: Fifty-eight formalin fixed paraffin blocks from diagnosed cases of prostatic tumours 
with different grade, and stages were included in this study. Ki-67 expression was examined 
immunohistochemically by using monoclonal mouse anti-human Ki67 IS626. The results were correlated with 
Gleason score and tumour differentiation and stage. 
RESULTS: The frequency of histological types was as follow: 11 cases of benign prostate,atic hyperplasia (19%) 
and 47 cases of prostatic cancer (81%). Our results stated that prostatic adenocarcinoma among Sudanese 
patients was of low grade which means tumours are less aggressive. Furthermore, the findings demonstrate that 
Ki-67 expression in prostatic carcinoma smears was correlated significantly with the degree of Gleason score (P < 
0.05). 
CONCLUSIONS: We found that the prostatic adenocarcinoma among Sudanese patients was less aggressive. 
Furthermore, Ki-67 expression was proportional to the grade of a tumour and it was a useful prognostic and 
diagnostic biomarker. 
 
 
 
 
 
Introduction 
 
Prostatic cancer is the second most common 
cancer of males in Western societies and those 
emulating Western lifestyles and diets. It was the 
fourth of the top 10 cancers found in Khartoum state – 
Sudan between 2009 -2010 (rate = 7.3 per 100,000) 
[1]. In the United States, the new cases were 
estimated to be 11,500; approximately one in seven 
American men diagnosed with prostate cancer during 
their lifetime [2]. Detection of this disease earlier, as a 
consequence of the introduction of the prostate-
specific antigen (PSA) blood test, has been 
acknowledged by the National Cancer Institute (NCI) 
as one factor contributing to lowering the mortality rate 
over the past few years [3]. The factors that determine 
the risk of developing clinical prostate Cancer are not 
well known; however, a few have been identified; an 
important risk factor seems to be heredity (4). The 
most important risk factor such as food consumption, 
the pattern of sexual behaviour, alcohol consumption, 
exposure to ultraviolet radiation and occupational 
exposure have all been discussed as being of 
etiological importance [5]. Other factors increasing risk 
include low intakes of vitamin E, selenium, lignans 
and isoflavonoids [6]. The reviewed international 
trends in prostate cancer mortality and reported 
significant reductions in prostate-cancer mortality in 
the UK, USA, Austria, Canada, Italy, France, 
Germany, Australia and Spain with downward trends 
in the Netherlands, Ireland and Sweden [7]. Detection 
of this disease earlier, as a consequence of the 
introduction of the prostate-specific antigen (PSA) 
blood test, has been acknowledged by the National 
Cancer Institute (NCI) as one factor contributing to 
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lowering the mortality rate over the past few years. 
The use of PSA testing has been estimated to provide 
a diagnostic lead-time of up to 10 years [3] [8]. Ki-67 
is a novel proliferative marker that can be readily 
detected by immunohistochemistry. The expression of 
Ki-67 is shown in all stages of the cell cycle, except 
G0, whereas resting cells entering from G0 lack Ki-67 
in the early part of G1 [9]. The fact makes it an 
excellent marker for determining the so-called growth 
fraction of a given cell population. The usefulness of 
the Ki-67 labelling index has been well established for 
various types of malignant neoplasms [10]. Ki scoring 
is essential for diagnosis for tumour grade, based on 
proportional of tumour-positive cells has usually used 
as in indication for evaluation, and many reports have 
shown clinical significance in a variety of cancers 
regardless of whether the origins epithelial or non-
epithelial [11]. The concordance rate of the Ki was 
determined by classifying the Ki 67 into less than 5% 
(< 5%) per 100/high power field (HPF), scored as zero 
(low), 5%-10% per 100/HPF, scored as 1 
(intermediate), and higher than 10% (10% <) per 
100/HPF, scored as 2 and 3(higher) [12]. Tissue 
microarrays (TMAs) are now widely accepted as a fast 
and cost-effective tool for use in almost any 
application requiring in situ tissue analysis [13]. 
According to its applications, TMAs was classified into 
predictive TMAs used to establish markers that predict 
response to therapy [14] and TMAs for validation of 
markers discovered by extracted protein, DNA- or 
RNA-based studies [15]. TMAs used to correlate 
staining results with clinical endpoints [16].  
To the best of our knowledge, this is the first 
study to score ki-67 expression in prostatic cancer 
among Sudanese patients. The overall objective of 
this study was to improve the diagnostic and 
prognostic by investigating the expression of ki-67 this 
will provide data which may help in better 
management and control of this disease.  
 
 
Material and Methods 
 
This is a descriptive retrospective study, was 
conducted at the University of Science and 
Technology to Laboratories Administration and 
different laboratories in Khartoum State, Sudan.  
A total of 58 patient, 11 cases of benign 
prostatic hyperplasia and 47 cases of prostate 
cancers were collected, and immunohistochemical 
staining was performed to evaluate the expression of 
Ki-67. The study was approved by the local Ethics 
Committee of the University of Science and 
Technology. Poorly fixed, overheated and too tiny 
specimen where excluded. 
Formalin-fixed paraffin-embedded tissue 
blocks were sectioned by using Rotary microtome and 
low profile disposable knives by using 4 microns as 
the thickness of choice. Sections were then floated on 
a floating water bath adjusted to 45°C. Finally, clear-
coated glass slides were used to pick up the floated 
sections and slides were left in a 60°C overnight in a 
hot air oven. Next day after oven drying sections were 
subjected to xylene and then to decrease graded of 
alcohols (100%, 90%, 70%, and 50%) for dehydration. 
The section was boiled in preheated retrieval buffer, 
performed in citrate buffer with pH 6.0 for 40 min at 
95°C in a water bath followed by cooling at a 
refrigerator for 10 min. After cooling the slides, 
Phosphate Buffer Saline (PBS) was added to the 
slides for 5 min. Endogenous peroxidase activity was 
blocked by incubation with 3% hydrogen peroxide 
(Envision FLEX Peroxidase-Blocking reagent 
K8000/K8010) for 7 min and then washed with PBS 
for 7 min. The slides were then incubated with primary 
antibody (monoclonal mouse anti-human Ki67 IS626) 
for 30 min followed by phosphate buffer saline for 7 
min. Then the slides were incubated with secondary 
antibody (EnVision FLEX/HRP K8000/K8010) for 30 
min, and then washed with PBS for 7min, and also 
sections were incubated with streptavidin peroxidase. 
Substrate-DAB Chromogen (K8000/K8010 Substrate 
Working Mix) was added for 10 min. The DAB 
Chromogen was prepared as described by the 
manufacturer (Dako) by adding one drop from the 
chromogen to 1ml of the substrate buffer. Slides were 
then washed in distilled water for 20 min and 
counterstained with Mayer's hematoxylin. The slides 
were evaluated individually in a standard light 
microscope for immunohistochemical staining. 
Positive controls were included from the beginning. 
A hundred fields were examined for Ki-67 
expression. Expression of Ki-67 less than 5 per cent 
per 100 high power fields (HPF) was scored as zero 
(low). Expression from 5 to 10 per cent of Ki-67 per 
100/(HPF) was scored as 1 (intermediate) and 
expression more than 30 per cent of ki-67 per 
100/(HPF) was scored as 2 and 3 (high) [10].  
Data were analysed by using the Statistical 
Package for the Social Sciences 20.0, SPSS, Inc., 
Chicago, IL) (SPSS). 
 
 
 
Results 
 
Fifty-eight cases of a prostate tumour were 
included in this study, patients’ age ranged between 
50-82 years with (mean 66 years). The frequency of 
histological types was as follow; 11 cases of benign 
prostatic hyperplasia (19%) and 47 cases of prostatic 
cancer (81%). 27 cases of low grade (57.4%), 20 
cases of high grade (42.6%). Table 1, shows there 
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was a significant correlation between age and 
prostatic cancer (P < 0.05). 
Table 1: Association between age and diagnosis cross 
tabulation 
Cross-tabulation 
Diagnosis  
Total B.PH CA 
Age group (Years) 
  
(50-60) 11 1 12 
(61-70) 0 20 20 
(71-82) 0 26 26 
Total 11 47 58 
 Chi square p value = 0.000** 
Chi-square p-value less than 0.05 that’s considered as statistically significant. ** 
Significant. 
 
According to the Ki-67 expression among 
different tumour grades in the current study, the 
Gleason scoring was: twenty-seven cases of low-
grade prostatic cancer were included, 74% cases 
were scored as score zero, while the remaining cases 
(16%) were scored as score 1 shown in Figure 1. On 
the other hand, Twenty cases of high-grade prostatic 
cancer were involved in this study; fourteen cases 
were scored as score 1, only two cases were scored 
as score 2 whereas the remaining three cases scored 
as score 3 as shown in Table 2. 
 
Figure 1: Expression of Ki-67 in malignant prostatic cancer 
 
The result showed that there was a significant 
correlation between Ki-67 score and tumour grades (P 
< 0.05). This means that a high score is associated 
with increased Gleason grade as shown in Figure 2. 
Table 2: Association between scoring (Gleason) Ki-67 and 
Grading cross tabulation 
Cross-tabulation 
Grading 
 
Total 
Percentage Percentage 
Low grade 
High 
grade 
Of low 
grade 
High grade 
Scoring 
(Gleason) 
KI67 
Low (<5% = Score 0) 20 1 21 95.5% 4.7% 
Intermediate (5-10% = Score1) 7 14 21 33.3% 66.6% 
High (score 2 =10-30% and score 3 
= >30%) 0 5 5 
 
00.0% 
 
100% 
Total 27 20 47   
Chi square p value = 0.000**    
Chi-square p-value less than 0.05 that’s considered as statistically significant. ** 
Significant. 
 
 
Figure 2: Distribution of scoring (Gleason) Ki-67 in low and high 
grade 
 
 
 
Discussion 
 
Prostatic cancer is one of the serious types of 
carcinomas that affect men all over the world. 
Although no strong data is available, a significant 
increase in the disease is noticed in Sudan. In this 
study, the expression of Ki-67 in 47 cases of prostatic 
adenocarcinoma was evaluated and scored according 
to KI Score system. In this study found that Ki-67 
expression was significantly is low in benign prostatic 
hyperplasia (19%) as compared with prostatic 
carcinoma (81%), (P < 0.05). This finding is in 
agreement with Nornazirah et al., [17] and Renuka et 
al., [18] who also found that the ki67 marker is highly 
expressed in prostate carcinoma as compared with 
benign prostatic hyperplasia, (P = 0.01) and (P = 0.05) 
respectively. The results found in this study 
concerning the patient age is acceptable and in 
comparison to global age. Older ages who found the 
most vulnerable group in this study is agreement with 
Fantony et al., [19] and Mohamed S A. Aziz et al., [20] 
who stated that with increasing age, men are 
significantly more likely to have high-risk prostate 
cancer. It is also in agreement with the American 
Cancer Society report (2016) that Prostate cancer is 
very rare in men younger than 40. About 60% of all 
prostate cancer cases are diagnosed in men 65 years 
of age and older, and 97% occur in men 50 and older 
[21].  
In this study, there were significant 
differences between different prostatic Gleason 
scores. Since Ki-67 is a proliferative biomarker 
indicating proliferation of tumour cells expressing it is 
expected to be associated with the aggressiveness of 
the tumour proliferation index [22]. This explains the 
results that no Ki-67 expression was detected among 
benign prostatic tumours. In contrast, positive staining 
of Ki-67 was detected in all cases of prostatic 
malignancy regardless of tumour grade.  
In the current studied group when the 
Gleason’s score correlated with expression of Ki-67, 
there was an increased expression of Ki-67 with the 
increase in the grade of a tumour. This is strongly 
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agreed with Sulik and Guzinska who there was a 
relationship between Gleason score and high 
expression of Ki-67 in prostate cancers [23] it is also 
agreed with Bantis et al. their findings demonstrate 
that Ki-67 expression in prostatic carcinoma smears, 
correlated significantly with the degree of Gleason 
score [24]. Despite this agreement, Ojea et al. found 
that Ki-67 is less effective than classic factors such as 
PSA and Gleason score [25].  
In conclusion, we found that the prostatic 
adenocarcinoma among Sudanese patients was of 
low grade (Gleason’s score less than 4) which means 
tumours are less aggressive. Furthermore, Ki-67 
expression was proportional to the grade of a tumour 
and it was a useful prognostic biomarker. We 
recommend to investigate for Ki-67 expression 
routinely for the diagnoses of prostatic cancer and to 
extend the investigation to involve more tumour 
biomarkers. 
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